UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044156
Receipt number R000050420
Scientific Title Survey of physiological effects after drinking alcohol
Date of disclosure of the study information 2021/05/10
Last modified on 2022/08/08 10:14:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Survey of physiological effects after drinking alcohol

Acronym

Survey of physiological effects after drinking alcohol

Scientific Title

Survey of physiological effects after drinking alcohol

Scientific Title:Acronym

Survey of physiological effects after drinking alcohol

Region

Japan


Condition

Condition

Healthy subjects

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The transient effects of consuming beverages with different alcohol content on the body will be investigated in healthy adult males between the ages of 40 and 70.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Serum free testosterone, Drunkenness VAS Questionnaire

Key secondary outcomes

(Secondary outcomes)
Serum testosterone, serum DHEA-S, serum cortisol, plasma ACTH, blood lactate, blood pyruvate, serum creatinine, plasma glucose, serum uric acid, serum TG, serum amino acids, blood acetic acid, breath alcohol content.
(Safety evaluation)
Vital signs, physical measurements, adverse events.


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -investigator(s) and assessor(s) are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Take test food A on the day of the test.
Wash out (2 weeks or more)
Take placebo food on the day of the test.
Wash out (2 weeks or more)
Take test food B on the day of the test.

Interventions/Control_2

Take test food B on the day of the test.
Wash out (2 weeks or more)
Take test food A on the day of the test.
Wash out (2 weeks or more)
Take placebo food on the day of the test.

Interventions/Control_3

Take placebo food on the day of the test.
Wash out (2 weeks or more)
Take test food B on the day of the test.
Wash out (2 weeks or more)
Take test food A on the day of the test.

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

70 years-old >

Gender

Male

Key inclusion criteria

1.Japanese males who are between 40 and 70 years old at the time of obtaining written consent.
2.Subject with serum free testosterone levels below 11.8 pg/ml.
3.Subject who can drink moderate amounts of alcohol (about 500ml of beer).
4.Subject who has received sufficient explanation of the purpose and content of the research, has the ability to consent.

Key exclusion criteria

1.Subject who has been diagnosed as an alcoholic by a physician.
2.Subject who is taking medication or under medical treatment due to serious illness.
3.Subject who is under exercise therapy or dietetic therapy.
4.Subject who may develop allergies due to the test foods.
5.Subject with current or history of drug dependence.
6.Subject who is out of the hospital due to mental disorders (depression, etc.) or sleep disorders, or who have a history of mental illness in the past.
7.Subject with irregular life rhythms due to night shifts or shift work.
8.Subject with extremely irregular lifestyle habits such as eating and sleeping.
9.Subject who has an extremely unbalanced diet.
10.Serious diseases such as brain disease, malignant tumor, immune disease, diabetes, liver disease (hepatitis), renal disease, heart disease, thyroid disease, adrenal disease, and other serious current or past diseases such as metabolic disease those who have.
11.Subject who uses health foods, supplements, and medicines that affect male hormone.
12.Subject who has participated in other clinical studies within the past 3 months from the day of the consent acquisition or who is planning to participate in other clinical studies during the current study.
13.Subject who has blood collection or donation more than 200mL within the past 1 month or more than 400mL within the past 3 months from the day of the consent acquisition.
14.Subject who can't keep the daily records.
15.Subject who is judged as an inappropriate candidate according to the screening data.
16.Subject who is considered as an inappropriate candidate by the doctor in charge.

Target sample size

36


Research contact person

Name of lead principal investigator

1st name Daisuke
Middle name
Last name Ochitani

Organization

HUMA R&D CORP

Division name

Public Relations Department

Zip code

108-0014

Address

Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan

TEL

03-3431-1260

Email

ochitani@huma-rd.co.jp


Public contact

Name of contact person

1st name Daisuke
Middle name
Last name Ochitani

Organization

HUMA R&D CORP

Division name

Public Relations Department

Zip code

108-0014

Address

Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan

TEL

03-3431-1260

Homepage URL


Email

ochitani@huma-rd.co.jp


Sponsor or person

Institute

HUMA R&D CORP

Institute

Department

Personal name



Funding Source

Organization

Asahi Quality & Innovations, Ltd

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

NISHI-UMEDA Clinic for Asian Medical Collaboration Clinical Research Institutional Review Board

Address

West Umeda Building 3F 3-3-45 Umeda Kita-ku Osaka Japan,530-0001

Tel

06-4797-5660

Email

jimukyoku@amc-clinc.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 05 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

36

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 04 Month 15 Day

Date of IRB

2021 Year 04 Month 22 Day

Anticipated trial start date

2021 Year 05 Month 11 Day

Last follow-up date

2021 Year 08 Month 26 Day

Date of closure to data entry

2021 Year 09 Month 07 Day

Date trial data considered complete

2021 Year 09 Month 21 Day

Date analysis concluded

2021 Year 12 Month 31 Day


Other

Other related information



Management information

Registered date

2021 Year 05 Month 10 Day

Last modified on

2022 Year 08 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050420


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name